RepurpOS

Hypothyroidism

Disease intelligence for Hypothyroidism: 159 alterations and 81 ranked therapeutics from curated public databases.

US DALYs1.70MWHO GHE 2021 · all ages
Global DALYs13.92MWHO GHE 2021 · worldwide
US mortality57.7K deaths/yrWHO GHE 2021
Global mortality221.3K deaths/yrWHO GHE 2021 · worldwide
Spontaneous remissionHashimoto's (most common cause) is irreversible in majority; spontaneous recovery in <5%; subclinical hypothyroidism…
Best-intervention remissionT4 monotherapy normalizes TSH in nearly all patients and resolves symptoms in ~60%; up to 40% of T4-treated patients…
Gap sizeModerate — within the treated population, a large minority are inadequately treated by the standard-of-care T4…
Primary barrierframing/practice
Full remission profile →

Disease overview

Alterations
159
Molecular (A)
100
Clinical (B–E)
59
Direct drugs
18
Via biomarker
58
Natural agents
5
Natural products
67
Merged ranked
81
With trial/literature evidence
25

Sources: Open Targets, HPO, ClinicalTrials.gov, DGIdb, ChEMBL, OSMF Chronic Disease Review, PubMed MeSH, PubMed Literature · Pipeline phase 7 · Updated 2026-07-05

Remission & chronicity

Spontaneous remission
Hashimoto's (most common cause) is irreversible in majority; spontaneous recovery in <5%; subclinical hypothyroidism spontaneously normalizes in ~30-40% of cases within 2 years without treatment
Best-intervention remission
T4 monotherapy normalizes TSH in nearly all patients and resolves symptoms in ~60%; up to 40% of T4-treated patients remain symptomatic despite normalized TSH; T4+T3 combination or desiccated thyroid extract (DTE) preferred by ~50% of patients in blinded preference trials
Drug-free remission
Relapse after remission
Chronicity
Gap size
Moderate — within the treated population, a large minority are inadequately treated by the standard-of-care T4 monotherapy approach
Primary barrier
framing/practice
Barrier detail: Up to 40% of patients remain symptomatic on T4 despite guideline-defined adequate treatment; T3 combination and DTE are rarely offered in primary care despite guideline acknowledgment that a trial may be appropriate; TSH-only monitoring misses tissue-level hypothyroidism

Last SoC change: 2014 — ATA guidelines last updated; acknowledged T4/T3 combination as appropriate trial in symptomatic patients; 2019 ETA/BTA guidelines more explicitly acknowledged need for personalized approach; T4 monotherapy has been standard since 1980s displacement of DTE

Remission data layers: disease_db_100 · source-locked manual data · confidence: high

Identifiers: MONDO: MONDO:0005420 · MESH: D007037 · UMLS_CUI: C0020676

Alterations

159 total · Types A (molecular) through E (functional)

NameTypeSubtypeDirection FrequencyEvidenceSourcesLinks
Abnormal circulating thyroglobulin concentration Lab / Clinical Lab value Moderate HPO, Monarch
Abnormal vestibular function Pathology Pathological finding Moderate HPO, Monarch
Abnormality of metabolism/homeostasis Pathology Pathological finding Moderate HPO, Monarch
Attention deficit hyperactivity disorder Pathology Pathological finding Moderate HPO, Monarch
Autoimmune antibody positivity Pathology Pathological finding Moderate HPO, Monarch
Central hypothyroidism Pathology Pathological finding Moderate HPO, Monarch
Cochlear malformation Pathology Pathological finding Moderate HPO, Monarch
Compensated hypothyroidism Pathology Pathological finding Moderate HPO, Monarch
Congenital goiter Pathology Pathological finding Moderate HPO, Monarch
Congenital hypothyroidism Pathology Pathological finding Moderate HPO, Monarch
Congenital sensorineural hearing impairment Pathology Pathological finding Moderate HPO, Monarch
Conjugated hyperbilirubinemia Pathology Pathological finding Moderate HPO, Monarch
Constipation Pathology Pathological finding Moderate HPO, Monarch
Decreased circulating T4 concentration Lab / Clinical Lab value Moderate HPO, Monarch
Decreased circulating free T4 concentration Lab / Clinical Lab value Moderate HPO, Monarch
Delayed proximal femoral epiphyseal ossification Pathology Pathological finding Moderate HPO, Monarch
Delayed skeletal maturation Pathology Pathological finding Moderate HPO, Monarch
Depressed nasal bridge Pathology Pathological finding Moderate HPO, Monarch
Diminished ability to concentrate Pathology Pathological finding Moderate HPO, Monarch
Dry skin Pathology Pathological finding Moderate HPO, Monarch
Elevated circulating thyroid-stimulating hormone concentration Lab / Clinical Lab value Moderate HPO, Monarch
Facial edema Pathology Pathological finding Moderate HPO, Monarch
Fatigue Functional Functional test Moderate HPO, Monarch
Feeding difficulties in infancy Pathology Pathological finding Moderate HPO, Monarch
Goiter Pathology Pathological finding Moderate HPO, Monarch
Growth delay Pathology Pathological finding Moderate HPO, Monarch
Hearing impairment Pathology Pathological finding Moderate HPO, Monarch
Hoarse voice Pathology Pathological finding Moderate HPO, Monarch
Hyporeflexia Pathology Pathological finding Moderate HPO, Monarch
Hypothalamic hypothyroidism Pathology Pathological finding Moderate HPO, Monarch
Hypothyroidism Pathology Pathological finding Moderate HPO, Monarch
Hypotonia Pathology Pathological finding Moderate HPO, Monarch
Inappropriately normal thyroid-stimulating hormone level Lab / Clinical Lab value Moderate HPO, Monarch
Increased T3/T4 ratio Pathology Pathological finding Moderate HPO, Monarch
Increased circulating T4 concentration Lab / Clinical Lab value Moderate HPO, Monarch
Increased circulating thyroglobulin concentration Lab / Clinical Lab value Moderate HPO, Monarch
Intellectual disability Functional Functional test Moderate HPO, Monarch
Large posterior fontanelle Pathology Pathological finding Moderate HPO, Monarch
Lethargy Pathology Pathological finding Moderate HPO, Monarch
Macroglossia Pathology Pathological finding Moderate HPO, Monarch
Moon facies Pathology Pathological finding Moderate HPO, Monarch
Multinodular goiter Pathology Pathological finding Moderate HPO, Monarch
Muscle weakness Functional Functional test Moderate HPO, Monarch
Neurodevelopmental delay Pathology Pathological finding Moderate HPO, Monarch
Overweight Pathology Pathological finding Moderate HPO, Monarch
Prolonged neonatal jaundice Pathology Pathological finding Moderate HPO, Monarch
Reduced TSH response to thyrotrophin-releasing hormone stimulation test Lab / Clinical Lab value Moderate HPO, Monarch
Reduced circulating prolactin concentration Lab / Clinical Lab value Moderate HPO, Monarch
Reduced radioactive iodine uptake Lab / Clinical Lab value Moderate HPO, Monarch
Secondary amenorrhea Pathology Pathological finding Moderate HPO, Monarch
Short stature Pathology Pathological finding Moderate HPO, Monarch
Spastic diplegia Pathology Pathological finding Moderate HPO, Monarch
Thyroid carcinoma Pathology Pathological finding Moderate HPO, Monarch
Thyroid defect in oxidation and organification of iodide Pathology Pathological finding Moderate HPO, Monarch
Thyroid hypoplasia Pathology Pathological finding Moderate HPO, Monarch
Umbilical hernia Pathology Pathological finding Moderate HPO, Monarch
ADCY7
adenylate cyclase 7
Molecular Gene Emerging Open Targets
AGO2
argonaute RISC catalytic component 2
Molecular Gene Emerging Open Targets
APOBR
apolipoprotein B receptor
Molecular Gene Emerging Open Targets
ARID5B
AT-rich interaction domain 5B
Molecular Gene Emerging Open Targets
ATP5IF1
ATP synthase inhibitory factor subunit 1
Molecular Gene Emerging Open Targets
BACH2
BACH transcriptional regulator 2
Molecular Gene Emerging Open Targets
BHLHE40
basic helix-loop-helix family member e40
Molecular Gene Emerging Open Targets
Baseline Characteristics (Sex) of the Cases With Hypothyroidism and of the Rest of the Cohort Lab / Clinical Lab value Emerging ClinicalTrials.gov
Baseline Characteristics (Sum of Examinations) in Cases With an Indication of Hypothyroidism and Cases Without Lab / Clinical Lab value Emerging ClinicalTrials.gov
C12orf42
chromosome 12 open reading frame 42
Molecular Gene Emerging Open Targets
C1QTNF6
C1q and TNF related 6
Molecular Gene Emerging Open Targets
CAMK4
calcium/calmodulin dependent protein kinase IV
Molecular Gene Emerging Open Targets
CBLB
Cbl proto-oncogene B
Molecular Gene Emerging Open Targets
CCN4
cellular communication network factor 4
Molecular Gene Emerging Open Targets
CCR9
C-C motif chemokine receptor 9
Molecular Gene Emerging Open Targets
CD2
CD2 molecule
Molecular Gene Emerging Open Targets
CD226
CD226 molecule
Molecular Gene Emerging Open Targets
CEP128
centrosomal protein 128
Molecular Gene Emerging Open Targets
CGA
glycoprotein hormones, alpha polypeptide
Molecular Gene Emerging Open Targets
CHRNA9
cholinergic receptor nicotinic alpha 9 subunit
Molecular Gene Emerging Open Targets
CLNK
cytokine dependent hematopoietic cell linker
Molecular Gene Emerging Open Targets
CPVL
carboxypeptidase vitellogenic like
Molecular Gene Emerging Open Targets
CTLA4
cytotoxic T-lymphocyte associated protein 4
Molecular Gene Emerging Open Targets
CX3CR1
C-X3-C motif chemokine receptor 1
Molecular Gene Emerging Open Targets
DNASE1L3
deoxyribonuclease 1L3
Molecular Gene Emerging Open Targets
DUOX2
dual oxidase 2
Molecular Gene Emerging Open Targets
DUOXA2
dual oxidase maturation factor 2
Molecular Gene Emerging Open Targets
ELMO1
engulfment and cell motility 1
Molecular Gene Emerging Open Targets
FCRL3
Fc receptor like 3
Molecular Gene Emerging Open Targets
FLT3
fms related receptor tyrosine kinase 3
Molecular Gene Emerging Open Targets
FOXA2
forkhead box A2
Molecular Gene Emerging Open Targets
FOXE1
forkhead box E1
Molecular Gene Emerging Open Targets
FOXI1
forkhead box I1
Molecular Gene Emerging Open Targets
FYN
FYN proto-oncogene, Src family tyrosine kinase
Molecular Gene Emerging Open Targets
GLIS3
GLIS family zinc finger 3
Molecular Gene Emerging Open Targets
GPR35
G protein-coupled receptor 35
Molecular Gene Emerging Open Targets
HABP2
hyaluronan binding protein 2
Molecular Gene Emerging Open Targets
ICOS
inducible T cell costimulator
Molecular Gene Emerging Open Targets
IFIH1
interferon induced with helicase C domain 1
Molecular Gene Emerging Open Targets
IGF2BP2
insulin like growth factor 2 mRNA binding protein 2
Molecular Gene Emerging Open Targets
IGSF1
immunoglobulin superfamily member 1
Molecular Gene Emerging Open Targets
IL15
interleukin 15
Molecular Gene Emerging Open Targets
IL2RA
interleukin 2 receptor subunit alpha
Molecular Gene Emerging Open Targets
IL7R
interleukin 7 receptor
Molecular Gene Emerging Open Targets
INPP5D
inositol polyphosphate-5-phosphatase D
Molecular Gene Emerging Open Targets
IPCEF1
interaction protein for cytohesin exchange factors 1
Molecular Gene Emerging Open Targets
IRF4
interferon regulatory factor 4
Molecular Gene Emerging Open Targets
IRF5
interferon regulatory factor 5
Molecular Gene Emerging Open Targets
IRS4
insulin receptor substrate 4
Molecular Gene Emerging Open Targets
IYD
iodotyrosine deiodinase
Molecular Gene Emerging Open Targets
JAK1
Janus kinase 1
Molecular Gene Emerging Open Targets
KAT6B
lysine acetyltransferase 6B
Molecular Gene Emerging Open Targets
KCNJ10
potassium inwardly rectifying channel subfamily J member 10
Molecular Gene Emerging Open Targets
LPP
LIM domain containing preferred translocation partner in lipoma
Molecular Gene Emerging Open Targets
MACIR
macrophage immunometabolism regulator
Molecular Gene Emerging Open Targets
NFATC1
nuclear factor of activated T cells 1
Molecular Gene Emerging Open Targets
NFIA
nuclear factor I A
Molecular Gene Emerging Open Targets
NINJ2
ninjurin 2
Molecular Gene Emerging Open Targets
NKX2-5
NK2 homeobox 5
Molecular Gene Emerging Open Targets
NR3C1
nuclear receptor subfamily 3 group C member 1
Molecular Gene Emerging Open Targets
NRG1
neuregulin 1
Molecular Gene Emerging Open Targets
PANX1
pannexin 1
Molecular Gene Emerging Open Targets
PAX8
paired box 8
Molecular Gene Emerging Open Targets
PDE10A
phosphodiesterase 10A
Molecular Gene Emerging Open Targets
PDE8B
phosphodiesterase 8B
Molecular Gene Emerging Open Targets
PKN3
protein kinase N3
Molecular Gene Emerging Open Targets
PLEKHA1
pleckstrin homology domain containing A1
Molecular Gene Emerging Open Targets
PLGRKT
plasminogen receptor with a C-terminal lysine
Molecular Gene Emerging Open Targets
PTEN
phosphatase and tensin homolog
Molecular Gene Emerging Open Targets
PTPN22
protein tyrosine phosphatase non-receptor type 22
Molecular Gene Emerging Open Targets
RASGRP1
RAS guanyl releasing protein 1
Molecular Gene Emerging Open Targets
RHOF
ras homolog family member F, filopodia associated
Molecular Gene Emerging Open Targets
RNASET2
ribonuclease T2
Molecular Gene Emerging Open Targets
S1PR4
sphingosine-1-phosphate receptor 4
Molecular Gene Emerging Open Targets
SECISBP2
SECIS binding protein 2
Molecular Gene Emerging Open Targets
SH2B3
SH2B adaptor protein 3
Molecular Gene Emerging Open Targets
SH2D2A
SH2 domain containing 2A
Molecular Gene Emerging Open Targets
SLC26A4
solute carrier family 26 member 4
Molecular Gene Emerging Open Targets
SLC5A5
solute carrier family 5 member 5
Molecular Gene Emerging Open Targets
SPATA6
spermatogenesis associated 6
Molecular Gene Emerging Open Targets
SPDL1
spindle apparatus coiled-coil protein 1
Molecular Gene Emerging Open Targets
STAT4
signal transducer and activator of transcription 4
Molecular Gene Emerging Open Targets
SUOX
sulfite oxidase
Molecular Gene Emerging Open Targets
SYN2
synapsin II
Molecular Gene Emerging Open Targets
TANK
TRAF family member associated NFKB activator
Molecular Gene Emerging Open Targets
TBX21
T-box transcription factor 21
Molecular Gene Emerging Open Targets
TG
thyroglobulin
Molecular Gene Emerging Open Targets
THRA
thyroid hormone receptor alpha
Molecular Gene Emerging Open Targets
THRB
thyroid hormone receptor beta
Molecular Gene Emerging Open Targets
TLR3
toll like receptor 3
Molecular Gene Emerging Open Targets
TNFRSF11B
TNF receptor superfamily member 11b
Molecular Gene Emerging Open Targets
TNFRSF14
TNF receptor superfamily member 14
Molecular Gene Emerging Open Targets
TNFSF11
TNF superfamily member 11
Molecular Gene Emerging Open Targets
TPO
thyroid peroxidase
Molecular Gene Emerging Open Targets
TRHR
thyrotropin releasing hormone receptor
Molecular Gene Emerging Open Targets
TSHB
thyroid stimulating hormone subunit beta
Molecular Gene Emerging Open Targets
TSHR
thyroid stimulating hormone receptor
Molecular Gene Emerging Open Targets
TYK2
tyrosine kinase 2
Molecular Gene Emerging Open Targets
The Duration of Hypothyroidism Episode in the "Probable Iodine Induced" Category Lab / Clinical Lab value Emerging ClinicalTrials.gov
VAV3
vav guanine nucleotide exchange factor 3
Molecular Gene Emerging Open Targets
VEGFC
vascular endothelial growth factor C
Molecular Gene Emerging Open Targets
ZNF462
zinc finger protein 462
Molecular Gene Emerging Open Targets
ZNF800
zinc finger protein 800
Molecular Gene Emerging Open Targets

Therapeutics

Direct disease associations, biomarker-linked drugs, OSMF narrative-review natural agents, merged ranking, and clinical trial / literature evidence (top agents)

From opensourcemed.info/chronic-disease — Herbal treatments for hypothyroidism: an evidence-based review. Candidates for further study, not approved treatments.

DrugTypePhaseEvidence ScoreTrials & literatureSourcesLinks
CHOLESTYRAMINE Small molecule Approved Strong 100
7 pubs
View evidence
Open Targets, ChEMBL
FENOFIBRATE Small molecule Approved Strong 100
13 pubs
View evidence
Open Targets, ChEMBL
LEVOTHYROXINE SODIUM Small molecule Approved Strong 100
8 trials 2 Cochrane 2 Meta-analysis 12 Trial pubs 8 RCT
View evidence

Registry trials

  • NCT01769157 — Effects of L-carnitine on Hypothyroidism (COMPLETED) PHASE4
  • NCT04124705 — A Study of Armour® Thyroid Compared to Synthetic T4 (Levothyroxine) in Previously Hypothyroid Participants (COMPLETED) PHASE2
  • NCT05240911 — Individual Dosing of Levothyroxine After Thyroidectomy (UNKNOWN) NA
  • NCT00488644 — Combined Levothyroxine/Liothyronine Supplementation in Hypothyroid Patients With Brain Tumors (TERMINATED) NA
  • NCT01486667 — Thyroxin Treatment in Sub Clinical Hypothyroidism, on the Apnea Hypopnea Index Score, Lipids and Highly Sensitive CRP (UNKNOWN) PHASE3
  • NCT01574859 — Central Hypothyroidism and Cardiovascular Risk (COMPLETED)
  • NCT05412979 — A Study Evaluating the Safety and Efficacy of Hormone Replacement Therapy With ST-1891 Compared to Levothyroxine in Patients With Primary Hypothyroidism (COMPLETED) PHASE2
  • NCT03106935 — Recurrent Pregnancy Loss and Thyroid Disease (UNKNOWN) EARLY_PHASE1

Published literature

Open Targets, ChEMBL
LIOTHYRONINE SODIUM Small molecule Approved Strong 100
8 trials
View evidence

Registry trials

  • NCT00488644 — Combined Levothyroxine/Liothyronine Supplementation in Hypothyroid Patients With Brain Tumors (TERMINATED) NA
  • NCT05015725 — The Relationship Between Serum rT3 Concentrations, T3/T4 Ratio, and Symptoms/Quality of Life in Treated Hypothyroid Patients (COMPLETED)
  • NCT01800617 — A Study of T3 Therapy in Patients With Hypothyroidism (COMPLETED) PHASE2
  • NCT05682482 — LT4/LT3 Combination Therapy Versus LT4 Monotherapy in Patients with Autoimmune Hypothyroidism. (RECRUITING) PHASE3
  • NCT04782856 — Energy Metabolism in Thyroidectomized Patients (COMPLETED) PHASE2
  • NCT03926585 — Variations in the DIO2 and MCT10 Genes and Effect of Triiodothyronine Treatment (COMPLETED)
  • NCT06731764 — Novel Approaches to the Treatment of Hypothyroidism (RECRUITING) PHASE2, PHASE3
  • NCT06353555 — Efficacy of Thyroid Hormone Replacement for Secondary Hypothyroidism Following Intracerebral Hemorrhage (UNKNOWN) NA

Open Targets, ChEMBL
MECASERMIN Biologic Approved Strong 100
No indexed hits
View evidence
Open Targets, ChEMBL
OMEGA-3-ACID ETHYL ESTERS Small molecule Approved Strong 100
1 pubs
View evidence
Open Targets, ChEMBL
ACETAZOLAMIDE Repurposing Small molecule Approved Strong 95 ChEMBL
AMPHETAMINE Repurposing Small molecule Approved Strong 95 ChEMBL
BICALUTAMIDE Repurposing Small molecule Approved Strong 95 ChEMBL
CARBACHOL Repurposing Small molecule Approved Strong 95 ChEMBL
CIPROFLOXACIN Repurposing Small molecule Approved Strong 95 ChEMBL
CLOMIPRAMINE Repurposing Small molecule Approved Strong 95 ChEMBL
DIAZEPAM Repurposing Small molecule Approved Strong 95 ChEMBL
DICHLORPHENAMIDE Repurposing Small molecule Approved Strong 95 ChEMBL
DIETHYLSTILBESTROL Repurposing Small molecule Approved Strong 95 ChEMBL
EPIRUBICIN Repurposing Small molecule Approved Strong 95 ChEMBL
ESTRADIOL 3-BENZOATE Repurposing Small molecule Approved Strong 95
1 trials
View evidence

Registry trials

  • NCT05782725 — Subclinical Hypothyroidism and Normogonadotropic Anovulation (COMPLETED)

DGIdb
ETHOXZOLAMIDE Repurposing Small molecule Approved Strong 95 ChEMBL
FLUMAZENIL Repurposing Small molecule Approved Strong 95 ChEMBL
GEMCITABINE Repurposing Small molecule Approved Strong 95
1 Trial pubs 1 RCT
View evidence

Published literature

DGIdb
GLUCARPIDASE Repurposing Small molecule Approved Strong 95
No indexed hits
View evidence
DGIdb
HALOPERIDOL DECANOATE Repurposing Small molecule Approved Strong 95
No indexed hits
View evidence
DGIdb
IMATINIB Repurposing Small molecule Approved Strong 95
1 Trial pubs
View evidence

Published literature

DGIdb
IMIPRAMINE Repurposing Small molecule Approved Strong 95 ChEMBL
INDAPAMIDE Repurposing Small molecule Approved Strong 95 ChEMBL
INDOMETHACIN Repurposing Small molecule Approved Strong 95
6 pubs
View evidence
ChEMBL
ISOSORBIDE DINITRATE Repurposing Small molecule Approved Strong 95 ChEMBL
MAFENIDE Repurposing Small molecule Approved Strong 95 ChEMBL
MECAMYLAMINE Repurposing Small molecule Approved Strong 95 ChEMBL
METHAZOLAMIDE Repurposing Small molecule Approved Strong 95 ChEMBL
METHOXSALEN Repurposing Small molecule Approved Strong 95 ChEMBL
METOPROLOL Repurposing Small molecule Approved Strong 95 ChEMBL
MIANSERIN Repurposing Small molecule Approved Strong 95 ChEMBL
NALIDIXIC ACID Repurposing Small molecule Approved Strong 95
No indexed hits
View evidence
ChEMBL
NICOTINE Repurposing Small molecule Approved Strong 95
1 Meta-analysis
View evidence

Published literature

ChEMBL
NORFLOXACIN Repurposing Small molecule Approved Strong 95 ChEMBL
OFLOXACIN Repurposing Small molecule Approved Strong 95
No indexed hits
View evidence
ChEMBL
PHENYTOIN Repurposing Small molecule Approved Strong 95 ChEMBL
PRAZOSIN Repurposing Small molecule Approved Strong 95
19 pubs
View evidence
ChEMBL
SIROLIMUS Repurposing Small molecule Approved Strong 95 ChEMBL
SULBACTAM Repurposing Small molecule Approved Strong 95
No indexed hits
View evidence
ChEMBL
TACROLIMUS ANHYDROUS Repurposing Small molecule Approved Strong 95 ChEMBL
TAMOXIFEN Repurposing Small molecule Approved Strong 95 DGIdb
TAZOBACTAM Repurposing Small molecule Approved Strong 95
No indexed hits
View evidence
ChEMBL
TRETINOIN Repurposing Small molecule Approved Strong 95
No indexed hits
View evidence
DGIdb
TROGLITAZONE Repurposing Small molecule Approved Strong 95 ChEMBL
ERGOCALCIFEROL Small molecule Phase III Moderate 80 Open Targets
LEVOTHYROXINE Small molecule Phase III Moderate 80 Open Targets, ChEMBL
LIOTHYRONINE Small molecule Phase III Moderate 80 Open Targets, ChEMBL
DARAPLADIB Repurposing Small molecule Phase III Moderate 70 ChEMBL
FENRETINIDE Repurposing Small molecule Phase III Moderate 70 ChEMBL
THYROID Small molecule Phase II Moderate 60 Open Targets, ChEMBL
ASCORBIC ACID Small molecule Phase II Emerging 60 Open Targets
ANDROGRAPHOLIDE Repurposing Small molecule Phase II Emerging 50 DGIdb
ALPRENOLOL Repurposing Small molecule Phase II Emerging 45 ChEMBL
AMIFLOXACIN Repurposing Small molecule Phase II Emerging 45 ChEMBL
BROLAMFETAMINE Repurposing Small molecule Phase II Emerging 45 ChEMBL
CARZENIDE Repurposing Small molecule Phase II Emerging 45 ChEMBL
DIFLOXACIN Repurposing Small molecule Phase II Emerging 45 ChEMBL
DIMECAMINE Repurposing Small molecule Phase II Emerging 45 ChEMBL
ELLAGIC ACID Repurposing Small molecule Phase II Emerging 45 ChEMBL
ENISOPROST Repurposing Small molecule Phase II Emerging 45 ChEMBL
FENCAMFAMIN Repurposing Small molecule Phase II Emerging 45 ChEMBL
FLEROXACIN Repurposing Small molecule Phase II Emerging 45 ChEMBL
IDOXIFENE Repurposing Small molecule Phase II Emerging 45 ChEMBL
LYSERGIDE Repurposing Small molecule Phase II Emerging 45 ChEMBL
MERAFLOXACIN Repurposing Small molecule Phase II Emerging 45 ChEMBL
TENAMFETAMINE Repurposing Small molecule Phase II Emerging 45 ChEMBL
ZIDAPAMIDE Repurposing Small molecule Phase II Emerging 45 ChEMBL
FERROUS SULFATE Small molecule Phase I Emerging 35 Open Targets
Ashwagandha OSMF review Herbal Preclinical Emerging 30
1 Cochrane 1 Trial pubs 1 RCT
View evidence

Published literature

OSMF Chronic Disease Review
Desiccated Thyroid Extract (DTE) OSMF review Supplement Preclinical Emerging 30
1 pubs
View evidence
OSMF Chronic Disease Review
Iodine OSMF review Supplement Preclinical Emerging 30
8 trials 18 Cochrane 11 Meta-analysis 68 Trial pubs 26 RCT
View evidence

Registry trials

  • NCT02280330 — Iodine Status of Preschoolers Given Micronutrient Powder for 6 Months (COMPLETED) PHASE4
  • NCT01950260 — Early Levothyroxine Post Radioactive Iodine (COMPLETED) PHASE2, PHASE3
  • NCT01349634 — The Effects of Iodized Salt on Cognitive Development in Ethiopia (COMPLETED) NA
  • NCT04860622 — Normal Range of TSH and FT4 in Pregnancy (COMPLETED)
  • NCT03120221 — Iodine Status in Pregnant Women in Israel (UNKNOWN)
  • NCT04831957 — Hypothyroidism After the TAVI Procedure in Elderly Patients (RECRUITING) NA
  • NCT02190214 — Thyroid Disorders in Malaysia: A Nationwide Multicentre Study (COMPLETED)
  • NCT03180892 — Non-immune Related Hypothyroidism in Iodine Sufficient Area (COMPLETED)

Published literature

OSMF Chronic Disease Review
L-Carnitine OSMF review Supplement Preclinical Emerging 30
2 trials 1 Trial pubs 1 RCT
View evidence

Registry trials

  • NCT01769157 — Effects of L-carnitine on Hypothyroidism (COMPLETED) PHASE4
  • NCT03372772 — Effect of Levocarnitine Supplementation for the Management of Fatigue in Levothyroxine-Treated Hypothyroid Patients (UNKNOWN) NA

Published literature

OSMF Chronic Disease Review
Nigella sativa OSMF review Herbal Preclinical Emerging 30
1 Cochrane
View evidence

Published literature

OSMF Chronic Disease Review
BIFIDOBACTERIUM SPP. Small molecule Preclinical Emerging 15 Open Targets
HYDROXYCHLOROQUINE Small molecule Preclinical Emerging 15 Open Targets
PROPYLTHIOURACIL Small molecule Preclinical Emerging 15 Open Targets
THYROGLOBULIN Small molecule Preclinical Emerging 15 Open Targets
THYROTROPIN Small molecule Preclinical Emerging 15 Open Targets
THYROXINE Small molecule Preclinical Emerging 15 Open Targets
DrugTypePhaseEvidence ScoreTrials & literatureSourcesLinks
CHOLESTYRAMINE Small molecule Approved Strong 100
7 pubs
View evidence
Open Targets, ChEMBL
FENOFIBRATE Small molecule Approved Strong 100
13 pubs
View evidence
Open Targets, ChEMBL
LEVOTHYROXINE SODIUM Small molecule Approved Strong 100
8 trials 2 Cochrane 2 Meta-analysis 12 Trial pubs 8 RCT
View evidence

Registry trials

  • NCT01769157 — Effects of L-carnitine on Hypothyroidism (COMPLETED) PHASE4
  • NCT04124705 — A Study of Armour® Thyroid Compared to Synthetic T4 (Levothyroxine) in Previously Hypothyroid Participants (COMPLETED) PHASE2
  • NCT05240911 — Individual Dosing of Levothyroxine After Thyroidectomy (UNKNOWN) NA
  • NCT00488644 — Combined Levothyroxine/Liothyronine Supplementation in Hypothyroid Patients With Brain Tumors (TERMINATED) NA
  • NCT01486667 — Thyroxin Treatment in Sub Clinical Hypothyroidism, on the Apnea Hypopnea Index Score, Lipids and Highly Sensitive CRP (UNKNOWN) PHASE3
  • NCT01574859 — Central Hypothyroidism and Cardiovascular Risk (COMPLETED)
  • NCT05412979 — A Study Evaluating the Safety and Efficacy of Hormone Replacement Therapy With ST-1891 Compared to Levothyroxine in Patients With Primary Hypothyroidism (COMPLETED) PHASE2
  • NCT03106935 — Recurrent Pregnancy Loss and Thyroid Disease (UNKNOWN) EARLY_PHASE1

Published literature

Open Targets, ChEMBL
LIOTHYRONINE SODIUM Small molecule Approved Strong 100
8 trials
View evidence

Registry trials

  • NCT00488644 — Combined Levothyroxine/Liothyronine Supplementation in Hypothyroid Patients With Brain Tumors (TERMINATED) NA
  • NCT05015725 — The Relationship Between Serum rT3 Concentrations, T3/T4 Ratio, and Symptoms/Quality of Life in Treated Hypothyroid Patients (COMPLETED)
  • NCT01800617 — A Study of T3 Therapy in Patients With Hypothyroidism (COMPLETED) PHASE2
  • NCT05682482 — LT4/LT3 Combination Therapy Versus LT4 Monotherapy in Patients with Autoimmune Hypothyroidism. (RECRUITING) PHASE3
  • NCT04782856 — Energy Metabolism in Thyroidectomized Patients (COMPLETED) PHASE2
  • NCT03926585 — Variations in the DIO2 and MCT10 Genes and Effect of Triiodothyronine Treatment (COMPLETED)
  • NCT06731764 — Novel Approaches to the Treatment of Hypothyroidism (RECRUITING) PHASE2, PHASE3
  • NCT06353555 — Efficacy of Thyroid Hormone Replacement for Secondary Hypothyroidism Following Intracerebral Hemorrhage (UNKNOWN) NA

Open Targets, ChEMBL
MECASERMIN Biologic Approved Strong 100
No indexed hits
View evidence
Open Targets, ChEMBL
OMEGA-3-ACID ETHYL ESTERS Small molecule Approved Strong 100
1 pubs
View evidence
Open Targets, ChEMBL
ERGOCALCIFEROL Small molecule Phase III Moderate 80 Open Targets
LEVOTHYROXINE Small molecule Phase III Moderate 80 Open Targets, ChEMBL
LIOTHYRONINE Small molecule Phase III Moderate 80 Open Targets, ChEMBL
THYROID Small molecule Phase II Moderate 60 Open Targets, ChEMBL
ASCORBIC ACID Small molecule Phase II Emerging 60 Open Targets
FERROUS SULFATE Small molecule Phase I Emerging 35 Open Targets
BIFIDOBACTERIUM SPP. Small molecule Preclinical Emerging 15 Open Targets
HYDROXYCHLOROQUINE Small molecule Preclinical Emerging 15 Open Targets
PROPYLTHIOURACIL Small molecule Preclinical Emerging 15 Open Targets
THYROGLOBULIN Small molecule Preclinical Emerging 15 Open Targets
THYROTROPIN Small molecule Preclinical Emerging 15 Open Targets
THYROXINE Small molecule Preclinical Emerging 15 Open Targets
DrugTypePhaseEvidence ScoreTrials & literatureSourcesLinks
ACETAZOLAMIDE Repurposing via ADCY7 Small molecule Approved Strong 95 ChEMBL
AMPHETAMINE Repurposing via ADCY7 Small molecule Approved Strong 95 ChEMBL
BICALUTAMIDE Repurposing via ADCY7 Small molecule Approved Strong 95 ChEMBL
CARBACHOL Repurposing via ADCY7 Small molecule Approved Strong 95 ChEMBL
CIPROFLOXACIN Repurposing via ADCY7 Small molecule Approved Strong 95 ChEMBL
CLOMIPRAMINE Repurposing via ADCY7 Small molecule Approved Strong 95 ChEMBL
DIAZEPAM Repurposing via ADCY7 Small molecule Approved Strong 95 ChEMBL
DICHLORPHENAMIDE Repurposing via ADCY7 Small molecule Approved Strong 95 ChEMBL
DIETHYLSTILBESTROL Repurposing via ADCY7 Small molecule Approved Strong 95 ChEMBL
EPIRUBICIN Repurposing via ADCY7 Small molecule Approved Strong 95 ChEMBL
ESTRADIOL 3-BENZOATE Repurposing via CAMK4 Small molecule Approved Strong 95
1 trials
View evidence

Registry trials

  • NCT05782725 — Subclinical Hypothyroidism and Normogonadotropic Anovulation (COMPLETED)

DGIdb
ETHOXZOLAMIDE Repurposing via ADCY7 Small molecule Approved Strong 95 ChEMBL
FLUMAZENIL Repurposing via ADCY7 Small molecule Approved Strong 95 ChEMBL
GEMCITABINE Repurposing via CAMK4 Small molecule Approved Strong 95
1 Trial pubs 1 RCT
View evidence

Published literature

DGIdb
GLUCARPIDASE Repurposing via ARID5B Small molecule Approved Strong 95
No indexed hits
View evidence
DGIdb
HALOPERIDOL DECANOATE Repurposing via ARID5B Small molecule Approved Strong 95
No indexed hits
View evidence
DGIdb
IMATINIB Repurposing via ARID5B Small molecule Approved Strong 95
1 Trial pubs
View evidence

Published literature

DGIdb
IMIPRAMINE Repurposing via ADCY7 Small molecule Approved Strong 95 ChEMBL
INDAPAMIDE Repurposing via ADCY7 Small molecule Approved Strong 95 ChEMBL
INDOMETHACIN Repurposing via ADCY7 Small molecule Approved Strong 95
6 pubs
View evidence
ChEMBL
ISOSORBIDE DINITRATE Repurposing via ADCY7 Small molecule Approved Strong 95 ChEMBL
MAFENIDE Repurposing via ADCY7 Small molecule Approved Strong 95 ChEMBL
MECAMYLAMINE Repurposing via ADCY7 Small molecule Approved Strong 95 ChEMBL
METHAZOLAMIDE Repurposing via ADCY7 Small molecule Approved Strong 95 ChEMBL
METHOXSALEN Repurposing via ADCY7 Small molecule Approved Strong 95 ChEMBL
METOPROLOL Repurposing via ADCY7 Small molecule Approved Strong 95 ChEMBL
MIANSERIN Repurposing via ADCY7 Small molecule Approved Strong 95 ChEMBL
NALIDIXIC ACID Repurposing via ADCY7 Small molecule Approved Strong 95
No indexed hits
View evidence
ChEMBL
NICOTINE Repurposing via ADCY7 Small molecule Approved Strong 95
1 Meta-analysis
View evidence

Published literature

ChEMBL
NORFLOXACIN Repurposing via ADCY7 Small molecule Approved Strong 95 ChEMBL
OFLOXACIN Repurposing via ADCY7 Small molecule Approved Strong 95
No indexed hits
View evidence
ChEMBL
PHENYTOIN Repurposing via ADCY7 Small molecule Approved Strong 95 ChEMBL
PRAZOSIN Repurposing via ADCY7 Small molecule Approved Strong 95
19 pubs
View evidence
ChEMBL
SIROLIMUS Repurposing via ADCY7 Small molecule Approved Strong 95 ChEMBL
SULBACTAM Repurposing via ADCY7 Small molecule Approved Strong 95
No indexed hits
View evidence
ChEMBL
TACROLIMUS ANHYDROUS Repurposing via ADCY7 Small molecule Approved Strong 95 ChEMBL
TAMOXIFEN Repurposing via C1QTNF6 Small molecule Approved Strong 95 DGIdb
TAZOBACTAM Repurposing via ADCY7 Small molecule Approved Strong 95
No indexed hits
View evidence
ChEMBL
TRETINOIN Repurposing via BHLHE40 Small molecule Approved Strong 95
No indexed hits
View evidence
DGIdb
TROGLITAZONE Repurposing via ADCY7 Small molecule Approved Strong 95 ChEMBL
DARAPLADIB Repurposing via ADCY7 Small molecule Phase III Moderate 70 ChEMBL
FENRETINIDE Repurposing via ADCY7 Small molecule Phase III Moderate 70 ChEMBL
ANDROGRAPHOLIDE Repurposing via ATP5IF1 Small molecule Phase II Emerging 50 DGIdb
ALPRENOLOL Repurposing via ADCY7 Small molecule Phase II Emerging 45 ChEMBL
AMIFLOXACIN Repurposing via ADCY7 Small molecule Phase II Emerging 45 ChEMBL
BROLAMFETAMINE Repurposing via ADCY7 Small molecule Phase II Emerging 45 ChEMBL
CARZENIDE Repurposing via ADCY7 Small molecule Phase II Emerging 45 ChEMBL
DIFLOXACIN Repurposing via ADCY7 Small molecule Phase II Emerging 45 ChEMBL
DIMECAMINE Repurposing via ADCY7 Small molecule Phase II Emerging 45 ChEMBL
ELLAGIC ACID Repurposing via ADCY7 Small molecule Phase II Emerging 45 ChEMBL
ENISOPROST Repurposing via ADCY7 Small molecule Phase II Emerging 45 ChEMBL
FENCAMFAMIN Repurposing via ADCY7 Small molecule Phase II Emerging 45 ChEMBL
FLEROXACIN Repurposing via ADCY7 Small molecule Phase II Emerging 45 ChEMBL
IDOXIFENE Repurposing via ADCY7 Small molecule Phase II Emerging 45 ChEMBL
LYSERGIDE Repurposing via ADCY7 Small molecule Phase II Emerging 45 ChEMBL
MERAFLOXACIN Repurposing via ADCY7 Small molecule Phase II Emerging 45 ChEMBL
TENAMFETAMINE Repurposing via ADCY7 Small molecule Phase II Emerging 45 ChEMBL
ZIDAPAMIDE Repurposing via ADCY7 Small molecule Phase II Emerging 45 ChEMBL
DrugTypePhaseEvidence ScoreTrials & literatureSourcesLinks
Ashwagandha OSMF review Herbal Preclinical Emerging 30
1 Cochrane 1 Trial pubs 1 RCT
View evidence

Published literature

OSMF Chronic Disease Review
Desiccated Thyroid Extract (DTE) OSMF review Supplement Preclinical Emerging 30
1 pubs
View evidence
OSMF Chronic Disease Review
Iodine OSMF review Supplement Preclinical Emerging 30
8 trials 18 Cochrane 11 Meta-analysis 68 Trial pubs 26 RCT
View evidence

Registry trials

  • NCT02280330 — Iodine Status of Preschoolers Given Micronutrient Powder for 6 Months (COMPLETED) PHASE4
  • NCT01950260 — Early Levothyroxine Post Radioactive Iodine (COMPLETED) PHASE2, PHASE3
  • NCT01349634 — The Effects of Iodized Salt on Cognitive Development in Ethiopia (COMPLETED) NA
  • NCT04860622 — Normal Range of TSH and FT4 in Pregnancy (COMPLETED)
  • NCT03120221 — Iodine Status in Pregnant Women in Israel (UNKNOWN)
  • NCT04831957 — Hypothyroidism After the TAVI Procedure in Elderly Patients (RECRUITING) NA
  • NCT02190214 — Thyroid Disorders in Malaysia: A Nationwide Multicentre Study (COMPLETED)
  • NCT03180892 — Non-immune Related Hypothyroidism in Iodine Sufficient Area (COMPLETED)

Published literature

OSMF Chronic Disease Review
L-Carnitine OSMF review Supplement Preclinical Emerging 30
2 trials 1 Trial pubs 1 RCT
View evidence

Registry trials

  • NCT01769157 — Effects of L-carnitine on Hypothyroidism (COMPLETED) PHASE4
  • NCT03372772 — Effect of Levocarnitine Supplementation for the Management of Fatigue in Levothyroxine-Treated Hypothyroid Patients (UNKNOWN) NA

Published literature

OSMF Chronic Disease Review
Nigella sativa OSMF review Herbal Preclinical Emerging 30
1 Cochrane
View evidence

Published literature

OSMF Chronic Disease Review

Natural Products

67 natural products with the same evidence schema as repurposed drugs — registry trials, PubMed literature, and reference links (pipeline-ranked)

Reference lookups: GreenMedInfo · Examine.com

DrugTypePhaseEvidence ScoreTrials & literatureSourcesLinks
Ashwagandha Natural product Ayurvedic Preclinical Moderate 17
1 Trial pubs 1 RCT
View evidence
Examine.com, GreenMedInfo
L-Carnitine Natural product Amino acid Approved Moderate 17
2 trials 1 Trial pubs
View evidence

Registry trials

  • NCT01769157 — Effects of L-carnitine on Hypothyroidism (COMPLETED) PHASE4
  • NCT03372772 — Effect of Levocarnitine Supplementation for the Management of Fatigue in Levothyroxine-Treated Hypothyroid Patients (UNKNOWN) NA

Published literature

Examine.com, GreenMedInfo
Iron Natural product Nutraceutical Approved Emerging 16
3 trials 2 Cochrane 10 Trial pubs 2 RCT
View evidence

Registry trials

  • NCT02280330 — Iodine Status of Preschoolers Given Micronutrient Powder for 6 Months (COMPLETED) PHASE4
  • NCT05240911 — Individual Dosing of Levothyroxine After Thyroidectomy (UNKNOWN) NA
  • NCT00535561 — Iron Deficiency Anemia Can be an Indication for Treatment of Subclinical Hypothyroidism (COMPLETED) PHASE1

ClinicalTrials.gov
L-Carnitine Natural product Amino acid Approved Emerging 13
2 trials 1 Trial pubs
View evidence

Registry trials

  • NCT01769157 — Effects of L-carnitine on Hypothyroidism (COMPLETED) PHASE4
  • NCT03372772 — Effect of Levocarnitine Supplementation for the Management of Fatigue in Levothyroxine-Treated Hypothyroid Patients (UNKNOWN) NA

Published literature

Examine.com
Curcumin Natural product Food compound Phase I Emerging 10
1 trials
View evidence

Registry trials

  • NCT05975866 — The Effects of an Anti-inflammatory Diet With or Without Curcumin Supplementation on Anthropometric Measurements, Concentrations of Thyroid Hormones, Anti-TPO, and Systemic Inflammation in Plasma and NFK-B in Peripheral Blood Mononuclear Cells in Patients With Hashimato (UNKNOWN) NA

ClinicalTrials.gov
Vitamin C Natural product Nutraceutical Phase II Emerging 10
1 trials 1 RCT
View evidence

Registry trials

  • NCT05733078 — Effect of Vitamin C Supplementation in Patients With Primary Hypothyroidism (UNKNOWN) PHASE2

Published literature

GreenMedInfo
Vitamin D3 Natural product Nutraceutical Phase III Emerging 10
3 trials
View evidence

Registry trials

  • NCT07535671 — The Effect of a Patient Education Program on Vitamin D Levels and Health Beliefs Regarding Vitamin D Use (ACTIVE_NOT_RECRUITING) NA
  • NCT06276205 — Vitamin D & Levothyroxine Combination Versus Levothyroxine on Lipid Profile in Hypothyroidism (COMPLETED) PHASE3
  • NCT02301520 — Vitamin D, Iodine, and Lead Levels in Haitian Infants and Children. (COMPLETED)

GreenMedInfo
Zinc Natural product Nutraceutical Preclinical Emerging 10
1 Meta-analysis
View evidence

Published literature

GreenMedInfo
Magnesium Natural product Nutraceutical Approved Emerging 10
5 trials 1 Meta-analysis 2 RCT
View evidence

Registry trials

  • NCT04354896 — The Effect of Thyroid Hormone Therapy on Muscle Mass and Function in Older Adults With Subclinical Hypothyroidism (COMPLETED) PHASE4
  • NCT02832960 — The TRUST Trial - CardioVascular Imaging ECHO (COMPLETED) PHASE4
  • NCT02500342 — Effect of Thyroid Hormone Replacement on Fatigability in Untreated Older Adults With Subclinical Hypothyroidism (COMPLETED) PHASE4
  • NCT01853579 — The TRUST Study - Depression Substudy (COMPLETED) PHASE4
  • NCT02832934 — The TRUST Study - CardioVascular Imaging IMT (COMPLETED) PHASE4

Published literature

GreenMedInfo
Taurine Natural product Amino acid Preclinical Emerging 10
13 pubs
View evidence
GreenMedInfo
Vitamin E Natural product Nutraceutical Preclinical Emerging 10
31 pubs
View evidence
GreenMedInfo
Vitamin B12 Natural product Nutraceutical Approved Emerging 10
1 trials 1 Meta-analysis 3 Trial pubs 1 RCT
View evidence

Registry trials

  • NCT02280330 — Iodine Status of Preschoolers Given Micronutrient Powder for 6 Months (COMPLETED) PHASE4

Published literature

GreenMedInfo
Omega-3 Fatty Acids Natural product Nutraceutical Preclinical Emerging 10
1 trials
View evidence

Registry trials

  • NCT05019118 — Dietary Intervention With Únicla Dairy Products (DANTIAN) (UNKNOWN) NA

GreenMedInfo
Ashwagandha Natural product Ayurvedic Preclinical Emerging 7
1 Trial pubs 1 RCT
View evidence
Examine.com
Black Seed Oil Natural product Botanical Preclinical Emerging 7
No indexed hits
View evidence
GreenMedInfo
Selenium Natural product Nutraceutical Approved Emerging 7
2 trials 3 Meta-analysis 11 Trial pubs
View evidence

Registry trials

  • NCT05019118 — Dietary Intervention With Únicla Dairy Products (DANTIAN) (UNKNOWN) NA
  • NCT02280330 — Iodine Status of Preschoolers Given Micronutrient Powder for 6 Months (COMPLETED) PHASE4

Published literature

GreenMedInfo
Boswellia Natural product Botanical Preclinical Emerging 7
No indexed hits
View evidence
GreenMedInfo
Curcumin Natural product Food compound Preclinical Emerging 7
1 trials
View evidence

Registry trials

  • NCT05975866 — The Effects of an Anti-inflammatory Diet With or Without Curcumin Supplementation on Anthropometric Measurements, Concentrations of Thyroid Hormones, Anti-TPO, and Systemic Inflammation in Plasma and NFK-B in Peripheral Blood Mononuclear Cells in Patients With Hashimato (UNKNOWN) NA

GreenMedInfo
Ginseng Natural product Botanical Preclinical Emerging 7
No indexed hits
View evidence
GreenMedInfo
Saffron Natural product Botanical Preclinical Emerging 7
No indexed hits
View evidence
GreenMedInfo
Alpha-Lipoic Acid Natural product Nutraceutical Preclinical Emerging 7 GreenMedInfo
Melatonin Natural product Nutraceutical Preclinical Emerging 7 GreenMedInfo
Chamomile Natural product Botanical Preclinical Emerging 7 GreenMedInfo
Bacopa Natural product Ayurvedic Preclinical Emerging 7 GreenMedInfo
Cannabidiol Natural product Food compound Preclinical Emerging 2 GreenMedInfo
(5R)-5-phenyl-2,3,4,5-tetrahydro-1H-3-benzazepine-7,8-diol Natural product Food compound Preclinical Emerging 0 ChEMBL
Suramin Natural product Food compound Preclinical Emerging 0 ChEMBL
Alvocidib Natural product Food compound Preclinical Emerging 0 ChEMBL
Staurosporine Natural product Food compound Preclinical Emerging 0 ChEMBL
Lestaurtinib Natural product Food compound Preclinical Emerging 0 ChEMBL
Chrysin Natural product Food compound Preclinical Emerging 0 GreenMedInfo
Iodine Natural product Nutraceutical Preclinical Emerging 0 GreenMedInfo
Genistein Natural product Food compound Preclinical Emerging 0 GreenMedInfo
Hesperidin Natural product Food compound Preclinical Emerging 0 GreenMedInfo
Nigella Sativa (Aka Black Seed) Natural product Nutraceutical Preclinical Emerging 0 GreenMedInfo
Soy Natural product Nutraceutical Preclinical Emerging 0 GreenMedInfo
Thyroid Extract Natural product Nutraceutical Preclinical Emerging 0 GreenMedInfo
Guggul Natural product Nutraceutical Preclinical Emerging 0 GreenMedInfo
Polyphenols Natural product Nutraceutical Preclinical Emerging 0 GreenMedInfo
Isoflavones Natural product Nutraceutical Preclinical Emerging 0 GreenMedInfo
Soy Protein Natural product Nutraceutical Preclinical Emerging 0 GreenMedInfo
Gamma-Oryzanol Natural product Nutraceutical Preclinical Emerging 0 GreenMedInfo
Rice Bran Natural product Nutraceutical Preclinical Emerging 0 GreenMedInfo
Homeopathic Medicine: All Natural product Nutraceutical Preclinical Emerging 0 GreenMedInfo
Pycnogenol (Pine Bark) Natural product Nutraceutical Preclinical Emerging 0 GreenMedInfo
B-Complex Natural product Nutraceutical Preclinical Emerging 0 GreenMedInfo
Vitamin a Natural product Food compound Preclinical Emerging 0 GreenMedInfo
Broccoli Sprouts Natural product Nutraceutical Preclinical Emerging 0 GreenMedInfo
Black Pepper Natural product Nutraceutical Preclinical Emerging 0 GreenMedInfo
Ferulic Acid Natural product Nutraceutical Preclinical Emerging 0 GreenMedInfo
Thiamine (B-1) Natural product Nutraceutical Preclinical Emerging 0 GreenMedInfo
Bauhinia Purpurea Natural product Nutraceutical Preclinical Emerging 0 GreenMedInfo
Ayurvedic Formulation: Liv52 Natural product Nutraceutical Preclinical Emerging 0 GreenMedInfo
Lemon Balm Natural product Nutraceutical Preclinical Emerging 0 GreenMedInfo
Flavonoids Natural product Nutraceutical Preclinical Emerging 0 GreenMedInfo
Mango Natural product Nutraceutical Preclinical Emerging 0 GreenMedInfo
Muskmelon Natural product Nutraceutical Preclinical Emerging 0 GreenMedInfo
Watermelon Natural product Nutraceutical Preclinical Emerging 0 GreenMedInfo
Nobiletin Natural product Nutraceutical Preclinical Emerging 0 GreenMedInfo
Biochanin a Natural product Nutraceutical Preclinical Emerging 0 GreenMedInfo
Daidzein Natural product Food compound Preclinical Emerging 0 GreenMedInfo
Formononetin Natural product Nutraceutical Preclinical Emerging 0 GreenMedInfo
Phytoestrogens Natural product Nutraceutical Preclinical Emerging 0 GreenMedInfo
Ginsenosides Natural product Nutraceutical Preclinical Emerging 0 GreenMedInfo
Parsley Natural product Nutraceutical Preclinical Emerging 0 GreenMedInfo
Royal Jelly Natural product Nutraceutical Preclinical Emerging 0 GreenMedInfo
Fucoxanthin Natural product Nutraceutical Preclinical Emerging 0 GreenMedInfo

Alterations and therapeutics are aggregated from public databases (Open Targets, HPO, ChEMBL, DGIdb, and others). Natural agents are candidates from OSMF narrative reviews on opensourcemed.info/chronic-disease.html — not approved treatments. This page is for research orientation only — not medical advice.

Part of the Open Source Medicine Foundation Network

Open Source Medicine Foundation The OSMF hub — advancing open-source biomedical research infrastructure, tools, and evidence synthesis.
SpikeProtein.site Database and research resource on SARS-CoV-2 spike protein biology, persistence, and clinical implications.
Vaccine Data Navigator Open-access navigation tool for vaccine adverse event reporting and surveillance data.
VitalScan4PACVS Remote physiological monitoring study for post-acute COVID-19 vaccination syndrome.
PACVS Research Summit Annual summit convening researchers, clinicians, and patients on PACVS science.